{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:05:50Z","timestamp":1793124350228,"version":"4.5.0"},"reference-count":149,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404509"],"award-info":[{"award-number":["82404509"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.critrevonc.2026.105252","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T02:01:30Z","timestamp":1772848890000},"page":"105252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Advances in osteosarcoma research: Pathogenesis and emerging therapeutic strategies"],"prefix":"10.1016","volume":"222","author":[{"given":"Lige","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.critrevonc.2026.105252_bib1","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2) \u2013specific chimeric antigen receptor\u2013modified T cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105252_bib2","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41577-022-00694-4","article-title":"Immunomodulation by endothelial cells - partnering up with the immune system?","volume":"22","author":"Amersfoort","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105252_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.1030094","article-title":"Current and future targeted alpha particle therapies for osteosarcoma: Radium-223, actinium-225, and thorium-227","volume":"9","author":"Anderson","year":"2022","journal-title":"Front Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105252_bib4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13045-016-0373-z","article-title":"Natural compounds targeting major cell signaling pathways: a novel paradigm for osteosarcoma therapy","volume":"10","author":"Angulo","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105252_bib5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.semcancer.2019.05.018","article-title":"Novel therapeutic strategies for spinal osteosarcomas","volume":"64","author":"Anwar","year":"2020","journal-title":"Semin Cancer Biol."},{"key":"10.1016\/j.critrevonc.2026.105252_bib6","article-title":"Osteosarcoma: prognosis plateau warrants retinoblastoma pathway targeted therapy","volume":"1","author":"Ballatori","year":"2016","journal-title":"Signal Transduct. Target Ther."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105252_bib7","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nm.3074","article-title":"WNT signaling in bone homeostasis and disease: From human mutations to treatments","volume":"19","author":"Baron","year":"2013","journal-title":"Nat. Med"},{"key":"10.1016\/j.critrevonc.2026.105252_bib8","doi-asserted-by":"crossref","unstructured":"Bartholf DeWitt S., Hoskinson Plumlee S., Brighton H.E., Sivaraj D., Martz E.J., Zand M., et al. Loss of ATRX promotes aggressive features of osteosarcoma with increased NF-\u03baB signaling and integrin binding. JCI Insight. 7(17):e151583.","DOI":"10.1172\/jci.insight.151583"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105252_bib9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/gcc.10132","article-title":"Spectral karyotyping identifies recurrent complex rearrangements of chromosomes 8, 17, and 20 in osteosarcomas","volume":"36","author":"Bayani","year":"2003","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105252_bib10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41572-022-00409-y","article-title":"Osteosarcoma","volume":"8","author":"Beird","year":"2022","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105252_bib11","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1002\/jcp.26330","article-title":"Novel smoothened antagonists as anti-neoplastic agents for the treatment of osteosarcoma","volume":"233","author":"Bernardini","year":"2018","journal-title":"J. Cell Physiol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105252_bib12","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/annonc\/mdw009","article-title":"Whole-exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterations","volume":"27","author":"Bousquet","year":"2016","journal-title":"Ann. Oncol. J. Eur. Soc. Med Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105252_bib13","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3892\/ijmm.2017.3037","article-title":"Notch signaling pathway promotes osteogenic differentiation of mesenchymal stem cells by enhancing BMP9\/Smad signaling","volume":"40","author":"Cao","year":"2017","journal-title":"Int J. Mol. Med"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105252_bib14","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrc4000","article-title":"MEK1 and MEK2 inhibitors and cancer therapy: The long and winding road","volume":"15","author":"Caunt","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105252_bib15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ejca.2019.07.018","article-title":"Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study","volume":"119","author":"Cesne","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105252_bib16","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/CAD.0000000000000609","article-title":"Hedgehog pathway and smoothened inhibitors in cancer therapies","volume":"29","author":"Chahal","year":"2018","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.critrevonc.2026.105252_bib17","doi-asserted-by":"crossref","first-page":"7605","DOI":"10.1038\/s41598-017-07194-9","article-title":"Polyphyllin I suppresses human osteosarcoma growth by inactivation of wnt\/\u03b2-catenin pathway in vitro and in vivo","volume":"7","author":"Chang","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105252_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105684","article-title":"Advances in targeted therapy for osteosarcoma based on molecular classification","volume":"169","author":"Chen","year":"2021","journal-title":"Pharm. Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105252_bib19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41413-018-0009-8","article-title":"Super enhancer inhibitors suppress MYC driven transcriptional amplification and tumor progression in osteosarcoma","volume":"6","author":"Chen","year":"2018","journal-title":"Bone Res"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105252_bib20","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/s41588-023-01315-z","article-title":"Author correction: comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing","volume":"55","author":"Cort\u00e9s-Ciriano","year":"2023","journal-title":"Nat. Genet"},{"key":"10.1016\/j.critrevonc.2026.105252_bib21","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.canlet.2017.07.024","article-title":"Mesenchymal stroma: role in osteosarcoma progression","volume":"405","author":"Cortini","year":"2017","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105252_bib22","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","article-title":"A non-comparative multi-center randomized phase II study of nivolumab +\/\u2212 ipilimumab for patients with metastatic sarcoma (alliance A091401)","volume":"19","author":"D\u2019Angelo","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105252_bib23","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1038\/s41467-022-30874-8","article-title":"Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma","volume":"13","author":"D\u2019Angelo","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105252_bib24","doi-asserted-by":"crossref","unstructured":"Dani N., Olivero M., Mareschi K., van Duist M.M., Miretti S., Cuvertino S., et al. The MET oncogene transforms human primary bone-derived cells into osteosarcomas by targeting committed osteo-progenitors. 2012;","DOI":"10.1002\/jbmr.1578"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105252_bib25","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3390\/ph14050421","article-title":"ICG-001, an inhibitor of the \u03b2-catenin and cAMP response element-binding protein dependent gene transcription, decreases proliferation but enhances migration of osteosarcoma cells","volume":"14","author":"Danieau","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105252_bib26","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1200\/JCO.18.02374","article-title":"Randomized double-blind phase II study of regorafenib in patients with metastatic osteosarcoma","volume":"37","author":"Davis","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105252_bib27","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(20)30023-1","article-title":"Nivolumab in children and young adults with relapsed\/refractory solid tumors (ADVL1412): A Phase 1 \/ 2 Trial","volume":"21","author":"Davis","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105252_bib28","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2012.45.5766","article-title":"Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy","author":"Demetri","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105252_bib29","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1158\/2767-9764.CRC-25-0293","article-title":"A phase I, open-label, dose escalation study of enoblituzumab in children and young adults with B7-H3\u2013expressing relapsed or refractory solid tumors","volume":"5","author":"DeSantes","year":"2025","journal-title":"Cancer Res. Commun."},{"issue":"10_ement","key":"10.1016\/j.critrevonc.2026.105252_bib30","doi-asserted-by":"crossref","first-page":"A65","DOI":"10.1158\/2326-6074.TUMIMM14-A65","article-title":"Abstract A65: Immune modulation of natural killer cell adoptive transfer for the treatment of osteosarcoma lung metastastasis: targeting the PD-1\/ PDL-1 signaling pathway","volume":"3","author":"Dhupkar","year":"2015","journal-title":"Cancer Immunol. Res"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105252_bib31","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s13277-014-2631-4","article-title":"MALAT1 promotes the proliferation and metastasis of osteosarcoma cells by activating the PI3K\/akt pathway","volume":"36","author":"Dong","year":"2015","journal-title":"Tumor Biol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105252_bib32","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/annonc\/mdx157","article-title":"BET inhibitors: a novel epigenetic approach","volume":"28","author":"Doroshow","year":"2017","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105252_bib33","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S1470-2045(18)30742-3","article-title":"Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study","volume":"20","author":"Duffaud","year":"2019","journal-title":"Lancet Oncol."},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105252_bib34","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1200\/JCO.2011.37.4546","article-title":"Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children\u2019s oncology group","volume":"30","author":"Ebb","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"95","key":"10.1016\/j.critrevonc.2026.105252_bib35","doi-asserted-by":"crossref","first-page":"36780","DOI":"10.18632\/oncotarget.26377","article-title":"Targeting the Wnt\/\u03b2-catenin pathway in human osteosarcoma cells","volume":"9","author":"Fang","year":"2018","journal-title":"Oncotarget"},{"issue":"50","key":"10.1016\/j.critrevonc.2026.105252_bib36","doi-asserted-by":"crossref","first-page":"20212","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105252_bib37","doi-asserted-by":"crossref","first-page":"13561","DOI":"10.1021\/acs.jmedchem.2c01244","article-title":"Targeting extracellular signal-regulated protein kinase 1\/2 (ERK1\/2) in cancer: An update on pharmacological small-molecule inhibitors","volume":"65","author":"Fu","year":"2022","journal-title":"J. Med Chem."},{"key":"10.1016\/j.critrevonc.2026.105252_bib38","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.canlet.2017.08.036","article-title":"TNF-related apoptosis-inducing ligand (TRAIL) for bone sarcoma treatment: pre-clinical and clinical data","volume":"409","author":"Gamie","year":"2017","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105252_bib39","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.18632\/aging.202314","article-title":"Notch-1 promotes the malignant progression of osteosarcoma through the activation of cell division cycle 20","volume":"13","author":"Gao","year":"2020","journal-title":"Aging"},{"key":"10.1016\/j.critrevonc.2026.105252_bib40","doi-asserted-by":"crossref","unstructured":"Gaspar, N., Campbell-Hewson, Q., Gallego Melcon, S., Locatelli, F., Venkatramani, R., Hecker-Nolting, S., Gambart, M., Bautista, F., Thebaud, E., Aerts, I., Morland, B., Rossig, C., Canete Nieto, A., Longhi, A., Lervat, C., Entz-Werle, N., Strauss, S.J., Marec-Berard, P., Okpara, C.E., He, C., Dutta, L., Casanova, M., 2021. Phase I\/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)\u2606. ESMO Open 6, 100250. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100250.","DOI":"10.1016\/j.esmoop.2021.100250"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105252_bib41","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.3390\/cancers13081757","article-title":"Systematic review of recurrent osteosarcoma systemic therapy","volume":"13","author":"Gazouli","year":"2021","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105252_bib42","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nrendo.2017.16","article-title":"Germline and somatic genetics of osteosarcoma \u2014 connecting aetiology, biology and therapy","volume":"13","author":"Gianferante","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105252_bib43","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41571-021-00519-8","article-title":"Advancing therapy for osteosarcoma","volume":"18","author":"Gill","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105252_bib44","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/S1470-2045(18)30438-8","article-title":"Trabectedin and olaparib in patients with advanced and non-resectable bone and soft tissue sarcomas (TOMAS trial): a phase 1b study from the Italian Sarcoma Group","volume":"19","author":"Grignani","year":"2018","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105252_bib45","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S1470-2045(14)71136-2","article-title":"Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial","volume":"16","author":"Grignani","year":"2015","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105252_bib46","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1158\/2159-8290.CD-21-1714","article-title":"Spatial positioning and matrix programs of cancer-associated fibroblasts promote T-cell exclusion in human lung tumors","volume":"12","author":"Grout","year":"2022","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105252_bib47","doi-asserted-by":"crossref","first-page":"5389","DOI":"10.1007\/s10238-023-01216-9","article-title":"Overexpression of HSPB6 inhibits osteosarcoma progress through the ERK signaling pathway","volume":"23","author":"Guo","year":"2023","journal-title":"Clin. Exp. Med"},{"key":"10.1016\/j.critrevonc.2026.105252_bib48","doi-asserted-by":"crossref","first-page":"1579822","DOI":"10.3389\/fimmu.2025.1579822","article-title":"Emerging immunotherapies in osteosarcoma: From checkpoint blockade to cellular therapies","volume":"16","author":"Han","year":"2025","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105252_bib49","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105252_bib50","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11864-017-0464-2","article-title":"Osteogenic sarcoma: Systemic chemotherapy options for localized disease","volume":"18","author":"Harrison","year":"2017","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.critrevonc.2026.105252_bib51","first-page":"264","article-title":"Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: a report from the children\u2019s oncology group","volume":"172","author":"Hingorani","year":"2022","journal-title":"Eur. J. Cancer Oxf. Engl. 1990"},{"key":"10.1016\/j.critrevonc.2026.105252_bib52","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1476-4598-9-5","article-title":"Smoothened as a new therapeutic target for human osteosarcoma","volume":"9","author":"Hirotsu","year":"2010","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105252_bib53","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41413-024-00342-8","article-title":"Wnt\/\u03b2-catenin signaling components and mechanisms in bone formation, homeostasis, and disease","volume":"12","author":"Hu","year":"2024","journal-title":"Bone Res"},{"key":"10.1016\/j.critrevonc.2026.105252_bib54","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1186\/s12967-024-05803-6","article-title":"SLC38A5 suppresses ferroptosis through glutamine-mediated activation of the PI3K\/AKT\/mTOR signaling in osteosarcoma","volume":"22","author":"Huang","year":"2024","journal-title":"J. Transl. Med"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105252_bib55","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41571-021-00496-y","article-title":"Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes","volume":"18","author":"Huinen","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"27","key":"10.1016\/j.critrevonc.2026.105252_bib56","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1200\/JCO.2014.59.4895","article-title":"Osteosarcoma: Current treatment and a collaborative pathway to success","volume":"33","author":"Isakoff","year":"2015","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105252_bib57","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(19)30825-3","article-title":"Cabozantinib in patients with advanced ewing sarcoma or osteosarcoma (CABONE): A multicentre, single-arm, phase 2 trial","volume":"21","author":"Italiano","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105252_bib58","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1186\/s13018-023-04437-6","article-title":"Caulis spatholobi extracts inhibit osteosarcoma growth and metastasis through suppression of CXCR4\/PI3K\/AKT signaling","volume":"18","author":"Jiang","year":"2023","journal-title":"J. Orthop. Surg."},{"key":"10.1016\/j.critrevonc.2026.105252_bib59","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.omtn.2017.06.008","article-title":"miR-135b stimulates osteosarcoma recurrence and lung metastasis via notch and wnt\/\u03b2-catenin signaling","volume":"8","author":"Jin","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.critrevonc.2026.105252_bib60","doi-asserted-by":"crossref","unstructured":"Kaczanowska, S., Murty, T., Alimadadi, A., Contreras, C.F., Duault, C., Subrahmanyam, P.B., Reynolds, W., Gutierrez, N.A., Baskar, R., Wu, C.J., Michor, F., Altreuter, J., Liu, Y., Jhaveri, A., Duong, V., Anbunathan, H., Ong, C., Zhang, H., Moravec, R., Yu, J., Biswas, R., Van Nostrand, S., Lindsay, J., Pichavant, M., Sotillo, E., Bernstein, D., Carbonell, A., Derdak, J., Klicka-Skeels, J., Segal, J.E., Dombi, E., Harmon, S.A., Turkbey, B., Sahaf, B., Bendall, S., Maecker, H., Highfill, S.L., Stroncek, D., Glod, J., Merchant, M., Hedrick, C.C., Mackall, C.L., Ramakrishna, S., Kaplan, R.N., 2024. Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy. Cancer Cell 42, 35-51.e8. https:\/\/doi.org\/10.1016\/j.ccell.2023.11.011.","DOI":"10.1016\/j.ccell.2023.11.011"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105252_bib61","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/nrclinonc.2018.9","article-title":"Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa","volume":"15","author":"Khan","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105252_bib62","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s10555-014-9523-3","article-title":"Significance of MTA1 in the molecular characterization of osteosarcoma","volume":"33","author":"Kim","year":"2014","journal-title":"Cancer Metastas.. Rev."},{"key":"10.1016\/j.critrevonc.2026.105252_bib63","first-page":"177","article-title":"Phase 2 trial of the GPNMB-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011) in recurrent osteosarcoma AOST1521: a report from the children\u2019s oncology group (COG)","volume":"121","author":"Kopp","year":"2019","journal-title":"Eur. J. Cancer Oxf. Engl. 1990"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105252_bib64","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ccell.2017.10.005","article-title":"Cancer-associated fibroblasts neutralize the anti-tumor effect of CSF1 receptor blockade by inducing PMN-MDSC infiltration of tumors","volume":"32","author":"Kumar","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2026.105252_bib65","doi-asserted-by":"crossref","first-page":"69","DOI":"10.21873\/anticanres.17924","article-title":"P53-armed oncolytic virotherapy promotes the efficacy of PD1 blockade in murine osteosarcoma tumors","volume":"46","author":"Kure","year":"2026","journal-title":"Anticancer Res."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105252_bib66","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1158\/2159-8290.CD-22-0192","article-title":"Stromal reprogramming by FAK inhibition overcomes radiation resistance to allow for immune priming and response to checkpoint blockade","volume":"12","author":"Lander","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105252_bib67","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s12951-021-01028-7","article-title":"The basic characteristics of extracellular vesicles and their potential application in bone sarcomas","volume":"19","author":"Li","year":"2021","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.critrevonc.2026.105252_bib68","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1186\/s12935-021-02411-y","article-title":"Cordycepin augments the chemosensitivity of osteosarcoma to cisplatin by activating AMPK and suppressing the AKT signaling pathway","volume":"21","author":"Li","year":"2021","journal-title":"Cancer Cell Int"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105252_bib69","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1007\/s11033-014-3193-7","article-title":"Epigenetic alterations in osteosarcoma: promising targets","volume":"41","author":"Li","year":"2014","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.critrevonc.2026.105252_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1394339","article-title":"Advancements in osteosarcoma management: integrating immune microenvironment insights with immunotherapeutic strategies","volume":"12","author":"Liang","year":"2024","journal-title":"Front Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105252_bib71","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12199-019-0835-3","article-title":"Blocking the PD-1\/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo","volume":"24","author":"Liu","year":"2019","journal-title":"Environ. Health Prev. Med."},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105252_bib72","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1101\/gad.307439.117","article-title":"Ets2 anchors the prometastatic function of mutant p53 in osteosarcoma","volume":"31","author":"Liu","year":"2017","journal-title":"Genes Dev."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105252_bib73","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7303","article-title":"The role of programmed cell death in osteosarcoma: From pathogenesis to therapy","volume":"13","author":"Liu","year":"2024","journal-title":"Cancer Med"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105252_bib74","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.apsb.2018.01.008","article-title":"Targeting ERK, an achilles\u2019 heel of the MAPK pathway, in cancer therapy","volume":"8","author":"Liu","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105252_bib75","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/cncr.28439","article-title":"Involvement and targeted intervention of dysregulated Hedgehog signaling in osteosarcoma","volume":"120","author":"Lo","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105252_bib76","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/0284186X.2018.1503714","article-title":"Pazopanib in relapsed osteosarcoma patients: Report on 15 cases","volume":"58","author":"Longhi","year":"2019","journal-title":"Acta Oncol."},{"key":"10.1016\/j.critrevonc.2026.105252_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107611","article-title":"New insights into molecular and cellular mechanisms of zoledronate in human osteosarcoma","volume":"214","author":"Lu","year":"2020","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.critrevonc.2026.105252_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.586580","article-title":"Macrophages in osteosarcoma immune microenvironment: Implications for immunotherapy","volume":"10","author":"Luo","year":"2020","journal-title":"Front Oncol."},{"issue":"38","key":"10.1016\/j.critrevonc.2026.105252_bib79","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/CJI.0000000000000065","article-title":"Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1\/PD-L1 interactions","volume":"1997","author":"Lussier","year":"2015","journal-title":"J. Immunother. Hagerstown Md"},{"key":"10.1016\/j.critrevonc.2026.105252_bib80","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1186\/s12935-021-02397-7","article-title":"Imperatorin induces autophagy and G0\/G1 phase arrest via PTEN-PI3K-AKT-mTOR\/p21 signaling pathway in human osteosarcoma cells in vitro and in vivo","volume":"21","author":"Lv","year":"2021","journal-title":"Cancer Cell Int"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105252_bib81","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.bbrc.2020.06.082","article-title":"Targeted MEK inhibition by cobimetinib enhances doxorubicin\u2019s efficacy in osteosarcoma models","volume":"529","author":"Ma","year":"2020","journal-title":"Biochem Biophys. Res Commun."},{"key":"10.1016\/j.critrevonc.2026.105252_bib82","article-title":"Palbociclib in solid tumor patients with genomic alterations in the cyclinD-cdk4\/6-INK4a-rb pathway: Results from NCI-COG pediatric MATCH trial arm I (APEC1621I)","volume":"8","author":"Macy","year":"2024","journal-title":"JCO Precis. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105252_bib83","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001561","article-title":"Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib\/II trial","volume":"8","author":"Martin-Broto","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105252_bib84","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1093\/annonc\/mdx536","article-title":"Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS)","volume":"28","author":"Martin-Broto","year":"2017","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105252_bib85","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/s41422-020-0370-1","article-title":"Wnt signaling and Loxl2 promote aggressive osteosarcoma","volume":"30","author":"Matsuoka","year":"2020","journal-title":"Cell Res"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105252_bib86","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1158\/1078-0432.CCR-15-0491","article-title":"Phase 1 clinical trial of ipilimumab In pediatric patients with advanced solid tumors","volume":"22","author":"Merchant","year":"2016","journal-title":"Clin. Cancer Res J. Am. Assoc. Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105252_bib87","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO.2008.14.0095","article-title":"Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival\u2014a report from the children\u2019s oncology group","volume":"26","author":"Meyers","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105252_bib88","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/cncr.24121","article-title":"Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the surveillance, epidemiology, and end results program","volume":"115","author":"Mirabello","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105252_bib89","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1002\/cncr.30606","article-title":"Phase 1\/2 study of immunotherapy with dendritic cells pulsed with autologous tumor lysate in patients with refractory bone and soft tissue sarcoma","volume":"123","author":"Miwa","year":"2017","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105252_bib90","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/nri3064","article-title":"The parallel lives of angiogenesis and immunosuppression: Cancer and other tales","volume":"11","author":"Motz","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105252_bib91","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.1158\/1078-0432.CCR-24-2519","article-title":"Histology-specific clinical trial of lenvatinib and pembrolizumab in patients with sarcoma","volume":"30","author":"Movva","year":"2024","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105252_bib92","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jconrel.2022.12.016","article-title":"Translational nanomedicine potentiates immunotherapy in sarcoma by normalizing the microenvironment","volume":"353","author":"Mpekris","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.critrevonc.2026.105252_bib93","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3389\/fonc.2013.00143","article-title":"Notch signaling is associated with ALDH activity and an aggressive metastatic phenotype in murine osteosarcoma cells","volume":"3","author":"Mu","year":"2013","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2026.105252_bib94","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.bone.2014.02.003","article-title":"Cells of origin in osteosarcoma: Mesenchymal stem cells or osteoblast committed cells?","volume":"62","author":"Mutsaers","year":"2014","journal-title":"Bone"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105252_bib95","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1002\/ijc.29107","article-title":"GLI2 is a novel therapeutic target for metastasis of osteosarcoma","volume":"136","author":"Nagao-Kitamoto","year":"2015","journal-title":"Int J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105252_bib96","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/jnci\/djz026","article-title":"Tegavivint and the \u03b2-catenin\/ALDH axis in chemotherapy-resistant and metastatic osteosarcoma","volume":"111","author":"Nomura","year":"2019","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2026.105252_bib97","article-title":"Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single-arm","volume":"131","author":"Palmerini","year":"2025","journal-title":"phase 2 trial. Cancer"},{"issue":"51","key":"10.1016\/j.critrevonc.2026.105252_bib98","doi-asserted-by":"crossref","first-page":"E5564","DOI":"10.1073\/pnas.1419260111","article-title":"Complementary genomic approaches highlight the PI3K\/mTOR pathway as a common vulnerability in osteosarcoma","volume":"111","author":"Perry","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105252_bib99","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41568-023-00658-3","article-title":"Translating p53-based therapies for cancer into the clinic","volume":"24","author":"Peuget","year":"2024","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105252_bib100","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1158\/1078-0432.CCR-12-2293","article-title":"The combination of sorafenib and everolimus abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models","volume":"19","author":"Pignochino","year":"2013","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105252_bib101","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1476-4598-8-118","article-title":"Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1\/2, MCL-1 and ezrin pathways","volume":"8","author":"Pignochino","year":"2009","journal-title":"Mol. Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105252_bib102","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1038\/bjc.2013.578","article-title":"Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery","volume":"109","author":"PosthumaDeBoer","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105252_bib103","doi-asserted-by":"crossref","first-page":"4734","DOI":"10.1002\/jcp.29351","article-title":"Bone marrow-derived mesenchymal stem cell-derived exosomal microRNA-208a promotes osteosarcoma cell proliferation, migration, and invasion","volume":"235","author":"Qin","year":"2020","journal-title":"J. Cell Physiol."},{"key":"10.1016\/j.critrevonc.2026.105252_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2023.110354","article-title":"Chitosan targets PI3K\/akt\/FoxO3a axis to up-regulate FAM172A and suppress MAPK\/ERK pathway to exert anti-tumor effect in osteosarcoma","volume":"373","author":"Ren","year":"2023","journal-title":"Chem. Biol. Inter."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105252_bib105","first-page":"1405","article-title":"Inhibitory effect of icariin on osteosarcoma cell proliferation via the wnt\/\u03b2-catenin signaling pathway","volume":"16","author":"Ren","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.critrevonc.2026.105252_bib106","unstructured":"Rosa, K., 2026. OST-HER2 meets primary end point of phase 2b trial in lung-only metastatic osteosarcoma | OncLive [WWW Document]. URL https:\/\/www.onclive.com\/view\/ost-her2-meets-primary-end-point-of-phase-2b-trial-in-lung-only-metastatic-osteosarcoma (accessed 1.18.26)."},{"key":"10.1016\/j.critrevonc.2026.105252_bib107","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41525-024-00430-y","article-title":"CDK4 is co-amplified with either TP53 promoter gene fusions or MDM2 through distinct mechanisms in osteosarcoma","volume":"9","author":"Saba","year":"2024","journal-title":"Npj Genom. Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105252_bib108","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3892\/ijo.2015.3236","article-title":"Combination of hedgehog inhibitors and standard anticancer agents synergistically prevent osteosarcoma growth","volume":"48","author":"Saitoh","year":"2016","journal-title":"Int J. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105252_bib109","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1158\/2159-8290.CD-17-1152","article-title":"Genome-informed targeted therapy for osteosarcoma","volume":"9","author":"Sayles","year":"2019","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105252_bib110","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1080\/14737140.2019.1652095","article-title":"Hedgehog pathway inhibition as a therapeutic target in acute myeloid leukemia","volume":"19","author":"Shallis","year":"2019","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105252_bib111","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41392-024-01828-x","article-title":"Notch signaling pathway in cancer: from mechanistic insights to targeted therapies","volume":"9","author":"Shi","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.critrevonc.2026.105252_bib112","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1005884","article-title":"A RUNX2-mediated epigenetic regulation of the survival of p53 defective cancer cells","volume":"12","author":"Shin","year":"2016","journal-title":"PLoS Genet."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105252_bib113","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1158\/2159-8290.CD-17-1355","article-title":"ERK inhibition: A new front in the war against MAPK pathway\u2013driven cancers?","volume":"8","author":"Smalley","year":"2018","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105252_bib114","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1470-2045(22)00392-8","article-title":"Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial","volume":"23","author":"Somaiah","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105252_bib115","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13045-024-01563-4","article-title":"Wnt\/\u03b2-catenin signaling pathway in carcinogenesis and cancer therapy","volume":"17","author":"Song","year":"2024","journal-title":"J. Hematol. OncolJ Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105252_bib116","doi-asserted-by":"crossref","first-page":"9656","DOI":"10.1002\/jcb.28244","article-title":"Long noncoding RNA OIP5-AS1 causes cisplatin resistance in osteosarcoma through inducing the LPAAT\u03b2\/PI3K\/AKT\/mTOR signaling pathway by sponging the miR-340-5p","volume":"120","author":"Song","year":"2019","journal-title":"J. Cell Biochem"},{"key":"10.1016\/j.critrevonc.2026.105252_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110544","article-title":"CCT128930 induces G1-phase arrest and apoptosis and synergistically enhances the anticancer efficiency of VS5584 in human osteosarcoma cells","volume":"130","author":"Sun","year":"2020","journal-title":"Biomed. Pharm."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105252_bib118","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/nm.3613","article-title":"Epigenetic targeting of hedgehog pathway transcriptional output through BET bromodomain inhibition","volume":"20","author":"Tang","year":"2014","journal-title":"Nat. Med"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105252_bib119","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft tissue and bone sarcomas: Results of SARC028, a multicentre, single arm, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105252_bib120","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/1078-0432.CCR-13-0103","article-title":"Molecular pathways: Response and resistance to BRAF and MEK inhibitors in BRAFV600E tumors","volume":"20","author":"Thakur","year":"2014","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105252_bib121","first-page":"163","article-title":"Mesenchymal stem cells promote tumor engraftment and metastatic colonization in rat osteosarcoma model","volume":"40","author":"Tsukamoto","year":"2012","journal-title":"Int J. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105252_bib122","unstructured":"University of Colorado, Denver, 2025. A phase I\/ib study of losartan in combination with sunitinib in the treatment of pediatric and adult patients with relapsed or refractory osteosarcoma (Clinical trial registration No. NCT03900793). clinicaltrials.gov."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105252_bib123","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth","volume":"41","author":"Visser","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2026.105252_bib124","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.biomaterials.2018.04.030","article-title":"Humanization of bone and bone marrow in an orthotopic site reveals new potential therapeutic targets in osteosarcoma","volume":"171","author":"Wagner","year":"2018","journal-title":"Biomaterials"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105252_bib125","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41419-018-0944-8","article-title":"Tolerance to sustained activation of the cAMP\/creb pathway activity in osteoblastic cells is enabled by loss of p53","volume":"9","author":"Walia","year":"2018","journal-title":"Cell Death Dis."},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105252_bib126","doi-asserted-by":"crossref","first-page":"11238","DOI":"10.3390\/ijms222011238","article-title":"Suppression of estrogen receptor alpha inhibits cell proliferation, differentiation and enhances the chemosensitivity of P53-positive U2OS osteosarcoma cell","volume":"22","author":"Wang","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105252_bib127","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1200\/JCO.2017.75.1743","article-title":"Osteosarcoma, chondrosarcoma, and chordoma","volume":"36","author":"Whelan","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105252_bib128","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.26426","article-title":"Incidence and survival of malignant bone sarcomas in England 1979\u20132007","volume":"131","author":"Whelan","year":"2012","journal-title":"Int J. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105252_bib129","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s13402-020-00514-8","article-title":"The PI3K\/mTOR dual inhibitor GSK458 potently impedes ovarian cancer tumorigenesis and metastasis","volume":"43","author":"Xiao","year":"2020","journal-title":"Cell Oncol."},{"key":"10.1016\/j.critrevonc.2026.105252_bib130","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1634\/theoncologist.2018-0542","article-title":"Apatinib for advanced osteosarcoma after failure of standard multimodal therapy: An open label phase II clinical trial","volume":"24","author":"Xie","year":"2019","journal-title":"The Oncologist"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105252_bib131","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000798","article-title":"Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, openlabel, phase 2 trial","volume":"8","author":"Xie","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105252_bib132","doi-asserted-by":"crossref","unstructured":"Yang J., Hu Y., Wang L., Sun X., Yu L., Guo W. Human umbilical vein endothelial cells derived-exosomes promote osteosarcoma cell stemness by activating notch signaling pathway. Bioengineered. 12(2):11007\u201311017.","DOI":"10.1080\/21655979.2021.2005220"},{"key":"10.1016\/j.critrevonc.2026.105252_bib133","first-page":"235","article-title":"Circular RNA circ_001422 promotes the progression and metastasis of osteosarcoma via the miR-195-5p\/FGF2\/PI3K\/akt axis","volume":"40","author":"Yang","year":"2021","journal-title":"J. Exp. Clin. Cancer Res CR"},{"issue":"1\u20132","key":"10.1016\/j.critrevonc.2026.105252_bib134","doi-asserted-by":"crossref","first-page":"484","DOI":"10.18632\/genesandcancer.133","article-title":"Genetically transforming human osteoblasts to sarcoma: Development of an osteosarcoma model","volume":"8","author":"Yang","year":"2017","journal-title":"Genes Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105252_bib135","doi-asserted-by":"crossref","first-page":"8792","DOI":"10.1002\/jcb.28167","article-title":"NK cell and macrophages confer prognosis and reflect immune status in osteosarcoma","volume":"120","author":"Yang","year":"2019","journal-title":"J. Cell Biochem"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105252_bib136","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/cac2.12377","article-title":"Targeting RAS mutants in malignancies: successes, failures, and reasons for hope","volume":"43","author":"Yang","year":"2022","journal-title":"Cancer Commun."},{"key":"10.1016\/j.critrevonc.2026.105252_bib137","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008744","article-title":"Targeting refractory\/recurrent neuroblastoma and osteosarcoma with anti-CD3\u00d7anti-GD2 bispecific antibody armed T cells","volume":"12","author":"Yankelevich","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105252_bib138","doi-asserted-by":"crossref","first-page":"4376","DOI":"10.7150\/ijbs.86214","article-title":"Beauvericin suppresses the proliferation and pulmonary metastasis of osteosarcoma by selectively inhibiting TGFBR2 pathway","volume":"19","author":"Ye","year":"2023","journal-title":"Int J. Biol. Sci."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105252_bib139","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/cpr.12204","article-title":"Epigenetic deregulations in chordoma","volume":"48","author":"Yu","year":"2015","journal-title":"Cell Prolif."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105252_bib140","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1158\/1541-7786.MCR-19-0493","article-title":"The notch pathway promotes osteosarcoma progression through activation of ephrin reverse signaling","volume":"17","author":"Yu","year":"2019","journal-title":"Mol. Cancer Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105252_bib141","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12943-024-02105-9","article-title":"Advances on immunotherapy for osteosarcoma","volume":"23","author":"Yu","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105252_bib142","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12951-021-00831-6","article-title":"Mitochondria-targeting graphene oxide nanocomposites for fluorescence imaging-guided synergistic phototherapy of drug-resistant osteosarcoma","volume":"19","author":"Zeng","year":"2021","journal-title":"J. Nanobiotechnology"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105252_bib143","doi-asserted-by":"crossref","first-page":"4908","DOI":"10.1016\/j.sjbs.2021.07.019","article-title":"Dieckol exerts anticancer activity in human osteosarcoma (MG-63) cells through the inhibition of PI3K\/AKT\/mTOR signaling pathway","volume":"28","author":"Zhang","year":"2021","journal-title":"Saudi J. Biol. Sci."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105252_bib144","doi-asserted-by":"crossref","first-page":"7900","DOI":"10.1021\/acs.jmedchem.0c02055","article-title":"Targeting epigenetic regulators with covalent small-molecule inhibitors","volume":"64","author":"Zhang","year":"2021","journal-title":"J. Med Chem."},{"key":"10.1016\/j.critrevonc.2026.105252_bib145","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13045-020-00990-3","article-title":"Targeting the Wnt\/\u03b2-catenin signaling pathway in cancer","volume":"13","author":"Zhang","year":"2020","journal-title":"J. Hematol. OncolJ Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105252_bib146","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41392-022-00934-y","article-title":"Notch signaling pathway: Architecture, disease, and therapeutics","volume":"7","author":"Zhou","year":"2022","journal-title":"Signal Transduct. Target Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105252_bib147","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000474","article-title":"Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103+ conventional dendritic cells","volume":"8","author":"Zhou","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105252_bib148","doi-asserted-by":"crossref","first-page":"6322","DOI":"10.1038\/s41467-020-20059-6","article-title":"Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma","volume":"11","author":"Zhou","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105252_bib149","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.toxicon.2021.04.024","article-title":"Melittin inhibits lung metastasis of human osteosarcoma: Evidence of wnt\/\u03b2-catenin signaling pathway participation","volume":"198","author":"Zhu","year":"2021","journal-title":"Toxicon"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T06:41:28Z","timestamp":1778481688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826001393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":149,"alternative-id":["S1040842826001393"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105252","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in osteosarcoma research: Pathogenesis and emerging therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105252","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105252"}}